In an article for Stat, Andrew Joseph writes that the Commonwealth Foundation for Cancer Research is committing $20 million to the Bridge Project, which funds research at the Koch Institute and Dana-Farber. “We’re looking for the best people, regardless of where they are, to tackle these very important problems,” explains Tyler Jacks, director of the Koch Institute.
In a new paper, Prof. Andrew Lo argues that the FDA should apply less stringent criteria when approving experimental drugs for terminal diseases that have few treatment options, writes Ed Silverman for The Boston Globe. “For terminal patients with no existing treatments, it seems to make sense to be more lenient,” says Lo.
Prof. Robert Horvitz speaks with Bloomberg TV’s Caroline Hyde about new developments in creating more effective treatments for cancer. Horvitz explains that “biologists have figured out what it is that keeps the immune system from, in general, attacking cancer cells and have learned to unleash that innate ability and attack a cancer in a patient.”
A team led by Prof. Michael Cima is developing an implantable sensor that can monitor a tumor’s response to cancer drugs, writes Eric Levenson for Boston.com. “The sensor would function like a long-term medical biopsy, giving doctors a continuous look at how a tumor is developing,” Levenson explains.
Jamie Ducharme writes for Boston Magazine that MIT researchers are developing a biochemical sensor that could provide updates on cancerous tumors. The sensor “could be implanted in cancerous tissue during a patient’s first biopsy. After that, it would stay in the tissue and transmit data about the state of the tumor to an external device.”
A new study on cancer drug development by MIT researchers found that pharmaceutical firms overlook drugs for early-stage tumors, writes Jordan Graham for The Boston Herald. “There’s dramatically more investments in the late-stage treatments,” says Prof. Benjamin Roin.
Scientific American reporter Cynthia Graber speaks with Prof. Sangeeta Bhatia about her new research that shows how bacteria could be used to detect cancer. “I think there's really a whole world of possibilities once you start thinking about using bacteria as a platform upon which to engineer functions,” says Bhatia.
MIT researchers have developed a test that can accurately detect cancer in urine, reports Megan Scudellari for The Boston Globe. “Bacteria can grow in tumors as small as 1 millimeter, so the urine test has the potential to detect liver tumors — which tend to be small and dispersed — very early on, which would improve survival rates for patients,” Scudellari explains.
Professor Sangeeta Bhatia and her colleagues have successfully engineered bacteria that can be used to detect cancer and diabetes, writes Robert Service for Science. The researchers found that “while conventional imaging techniques struggle to detect liver tumors smaller than 1 square centimeter, this approach was able to flag tumors as small as 1 square millimeter.”
Los Angeles Times reporter Melissa Healy writes that researchers from MIT and the University of California, San Diego have successfully modified bacteria to detect cancer. “Their work is a key component of broader efforts to make the diagnosis and treatment of diseases such as cancer increasingly precise and targeted," writes Healy.
Researchers from MIT and the University of California, San Diego have genetically modified bacteria so that it can detect cancer, BBC News reports. The researchers hope that one day, “the general approach could one day be used to develop relatively cheap and easy to use home-testing kits for a range of diseases.”
MIT researchers have developed a non-invasive way to detect liver cancer using probiotics, reports Vijee Venkatraman for BetaBoston. The researchers found that they could “use bacteria as tumor scouts…and engineer them to emit a signal once they reached the mass and multiply.”
Federico Guerrini of Forbes writes that a team of researchers involved with the Singapore-MIT Alliance for Research and Technology (SMART) is developing a 3-D microfluidic cell culture device to detect cancer. The device is a thick disk “in which the team has designed some ‘channels’ to study how the cells move inside the blood vessels and interact with each other.”
“MIT researchers have created an algorithm [that] can distinguish between different lymphomas in real time,” writes Melissa Malamut for Boston Magazine. Graduate student Yuan Luo and Professor Peter Szolovits developed a system that can automatically suggest cancer diagnoses based on data points from past pathology reports, Malamut explains.
Boston.com reporter Dialynn Dwyer writes about how graduate student Steven Keating “fought his cancer with curiosity.” Dwyer explains that Keating “gathered his health data in order to understand the science behind what his body was going through” and even filmed his brain surgery.